CINXE.COM

<!doctype html> <html data-n-head-ssr lang="de" data-n-head="%7B%22lang%22:%7B%22ssr%22:%22de%22%7D%7D"> <head > <title>Big Pharma News Today, Neuigkeiten aus der Pharmabranche - ECHEMI</title><meta data-n-head="ssr" charset="utf-8"><meta data-n-head="ssr" name="viewport" content="width=device-width, initial-scale=1"><meta data-n-head="ssr" name="format-detection" content="telephone=no"><meta data-n-head="ssr" data-hid="description" name="description" content="Holen Sie sich die neuesten und aktuellen Nachrichten aus der globalen Pharmaindustrie mit Neuigkeiten und Marketinganalysen von Top-Pharmaunternehmen. Behalten Sie die weltweiten Pharmatrends von ECHEMI im Auge."><meta data-n-head="ssr" data-hid="keywords" name="keywords" content="Tägliche Pharma-Nachrichten, Pharma-Wirtschaftsnachrichten, internationale Pharma-Nachrichten, aktuelle Nachrichten aus der pharmazeutischen Industrie"><link data-n-head="ssr" rel="icon" type="image/x-icon" href="/static/images/echemi.png"><script data-n-head="ssr" src="/static/js/flexible.js" type="text/javascript" chartset="utf-8"></script><script data-n-head="ssr" src="/static/js/google.js" type="text/javascript" chartset="utf-8"></script><script data-n-head="ssr" type="application/ld+json">{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://de.echemi.com"},{"@type":"ListItem","position":2,"name":"Nachrichten"},{"@type":"ListItem","position":3,"name":""}]}</script><link rel="preload" href="https://static-de.echemi.com/_nuxt/79ec1eb.js" as="script"><link rel="preload" href="https://static-de.echemi.com/_nuxt/d173603.js" as="script"><link rel="preload" href="https://static-de.echemi.com/_nuxt/css/8137e1b.css" as="style"><link rel="preload" href="https://static-de.echemi.com/_nuxt/d2fee69.js" as="script"><link rel="preload" href="https://static-de.echemi.com/_nuxt/css/d05de89.css" as="style"><link rel="preload" href="https://static-de.echemi.com/_nuxt/4fb1842.js" as="script"><link rel="preload" href="https://static-de.echemi.com/_nuxt/css/9faaf7d.css" as="style"><link rel="preload" href="https://static-de.echemi.com/_nuxt/db56bde.js" as="script"><link rel="preload" href="https://static-de.echemi.com/_nuxt/css/8154aa0.css" as="style"><link rel="preload" href="https://static-de.echemi.com/_nuxt/9919ef3.js" as="script"><link rel="preload" href="https://static-de.echemi.com/_nuxt/css/f84a2d6.css" as="style"><link rel="preload" href="https://static-de.echemi.com/_nuxt/6159f0f.js" as="script"><link rel="preload" href="https://static-de.echemi.com/_nuxt/css/a7ea1c9.css" as="style"><link rel="preload" href="https://static-de.echemi.com/_nuxt/8972da6.js" as="script"><link rel="stylesheet" href="https://static-de.echemi.com/_nuxt/css/8137e1b.css"><link rel="stylesheet" href="https://static-de.echemi.com/_nuxt/css/d05de89.css"><link rel="stylesheet" href="https://static-de.echemi.com/_nuxt/css/9faaf7d.css"><link rel="stylesheet" href="https://static-de.echemi.com/_nuxt/css/8154aa0.css"><link rel="stylesheet" href="https://static-de.echemi.com/_nuxt/css/f84a2d6.css"><link rel="stylesheet" href="https://static-de.echemi.com/_nuxt/css/a7ea1c9.css"> </head> <body > <div data-server-rendered="true" id="__nuxt"><div id="__layout"><div><div data-v-50e0ea6a><header class="border_color" data-v-50e0ea6a><div class="max_width" data-v-50e0ea6a><div class="flex flex_b flex_c" data-v-50e0ea6a><div class="header_left flex flex_c" data-v-50e0ea6a><div class="logo_box" data-v-50e0ea6a><a href="/" data-v-50e0ea6a><div class="head_logo1" data-v-50e0ea6a><img src="https://static-de.echemi.com/_nuxt/img/echemi.6fa7126.svg" alt="ECHEMI logo" data-v-50e0ea6a></div> <div class="head_logo2" data-v-50e0ea6a><img src="https://static-de.echemi.com/_nuxt/img/echemi-slogan.439bb9c.svg" alt data-v-50e0ea6a></div></a></div> <div class="menu" data-v-50e0ea6a><p data-v-50e0ea6a>Menü <i class="iconfont icon-xuelexialajiantou" data-v-50e0ea6a></i></p></div></div> <div class="header_right flex flex_c" data-v-50e0ea6a><div class="isearch_box flex flex_c" style="display:none;" data-v-50e0ea6a><div class="isearch_select_box" data-v-50e0ea6a><select data-v-50e0ea6a><option value="1" selected="selected" data-v-50e0ea6a>Produkte</option> <option value="2" data-v-50e0ea6a>Lieferanten</option> <option value="4" data-v-50e0ea6a>Anfrage</option></select> <i class="iconfont" data-v-50e0ea6a></i></div> <input type="text" placeholder="Bitte geben Sie den Produktnamen oder die CAS-NR. ein" value="" class="isearch_ipt" data-v-50e0ea6a> <i class="iconfont search_icon" data-v-50e0ea6a></i> <div id="search_box" class="search_box_content" style="display:none;" data-v-50e0ea6a><ul data-v-50e0ea6a></ul></div></div> <div class="input_div" style="display:;" data-v-50e0ea6a><i class="iconfont" data-v-50e0ea6a></i> <span data-v-50e0ea6a>Auf ECHEMI</span></div> <div class="language_box" data-v-50e0ea6a><div class="ul clearfix" data-v-50e0ea6a><div class="items" data-v-50e0ea6a><p class="box_shadow" data-v-50e0ea6a><i class="iconfont" data-v-50e0ea6a></i> <a href="javascript:void(0)" rel="nofollow" class="hover_a" data-v-50e0ea6a>Einloggen</a> | <a href="javascript:void(0)" rel="nofollow" class="hover_a" data-v-50e0ea6a>Kostenlos anmelden</a></p></div> <div class="items" data-v-50e0ea6a><p class="box_shadow p2" data-v-50e0ea6a><i class="iconfont" data-v-50e0ea6a></i> <a data-v-50e0ea6a>DE</a></p> <div class="menu_box menu_box2" data-v-50e0ea6a><ul data-v-50e0ea6a><li data-v-50e0ea6a><a href="https://www.echemi.com/cms-news/pharmaceutical.html" data-v-50e0ea6a>EN</a></li> <li data-v-50e0ea6a>DE</li></ul></div></div></div></div></div></div></div></header> <div class="header_nav" style="display:none;" data-v-50e0ea6a><ul class="nav_box max_width" data-v-50e0ea6a><li class="has_menu" data-v-50e0ea6a><a href="javascript:void(0)" data-v-50e0ea6a><p data-v-50e0ea6a>Kategorien </p><i class="iconfont" data-v-50e0ea6a></i></a></li> <li class="has_mi_cate" data-v-50e0ea6a><a href="/wholesale.html" data-v-50e0ea6a><p data-v-50e0ea6a>Großhandel</p><i class="iconfont" data-v-50e0ea6a></i></a></li> <li class="has_mi_cate" data-v-50e0ea6a><p data-v-50e0ea6a>Nachrichten</p><i class="iconfont" data-v-50e0ea6a></i></li></ul> <div class="cate_drop_menu" style="display:none;" data-v-50e0ea6a><div class="max_width flex" data-v-50e0ea6a><div class="cate_drop_menu_left" data-v-50e0ea6a><ul data-v-50e0ea6a></ul></div> <div class="cate_drop_menu_right" data-v-50e0ea6a><div class="cate_drop_menu_content" data-v-50e0ea6a></div> <div class="cate_drop_menu_bg" data-v-50e0ea6a></div></div></div></div> <div class="mi_drop_menu" data-v-50e0ea6a><div class="max_width flex" data-v-50e0ea6a><div class="mi_drop_menu_common Großhandel" style="display:none;" data-v-50e0ea6a><ul data-v-50e0ea6a><li data-v-50e0ea6a><a href="/wholesale/paints-and-coatings.html" data-v-50e0ea6a>Großhandel Farben und Beschichtungen</a></li> <li data-v-50e0ea6a><a href="/wholesale/food-ingredients.html" data-v-50e0ea6a>Großhandel Lebensmittelinhaltsstoffe</a></li> <li data-v-50e0ea6a><a href="/wholesale/pharmaceutical-raw-materials.html" data-v-50e0ea6a>Großhandel Pharmazeutische Rohstoffe</a></li> <li data-v-50e0ea6a><a href="/wholesale/fine-chemicals.html" data-v-50e0ea6a>Großhandel Feinchemikalien</a></li> <li data-v-50e0ea6a><a href="/wholesale/botanical-extracts.html" data-v-50e0ea6a>Großhandel Botanische Extrakten</a></li> <li data-v-50e0ea6a><a href="/wholesale/rubber-plastic-ingredients.html" data-v-50e0ea6a>Großhandel Gummi-Kunststoff-Inhaltsstoffe</a></li></ul></div> <div class="mi_drop_menu_common Nachrichten" style="display:none;" data-v-50e0ea6a><ul data-v-50e0ea6a><li data-v-50e0ea6a><a href="/cms-news/paint-coating.html" data-v-50e0ea6a>Nachrichten zu Farben&Beschichtungen</a></li> <li data-v-50e0ea6a><a href="/cms-news/food-additives.html" data-v-50e0ea6a>Nachrichten der Lebensmittelindustrie</a></li> <li data-v-50e0ea6a><a href="/cms-news/pharmaceutical.html" data-v-50e0ea6a>Pharmazeutische Nachrichten</a></li> <li data-v-50e0ea6a><a href="/cms-news/blog.html" data-v-50e0ea6a>Blogs</a></li> <li data-v-50e0ea6a><a href="/cms-news/faq.html" data-v-50e0ea6a>FAQ</a></li></ul></div></div></div></div> <div class="shield_div" style="display:none;" data-v-50e0ea6a></div></div> <div data-v-8abea6b2><div class="p_b_60 bg_white" data-v-a6ac6c5e data-v-8abea6b2><div class="max_width" data-v-a6ac6c5e><div class="crumb" style="color:#333;" data-v-53bbd022 data-v-a6ac6c5e><div data-v-53bbd022><a href="/" style="color:#333;" data-v-53bbd022>Hauptseite</a> > </div>  <div data-v-53bbd022><span data-v-53bbd022>Nachrichten</span> <a style="color:#333;" data-v-53bbd022></a> > </div> <div data-v-53bbd022> </div>    </div> <div class="content flex flex_b" data-v-a6ac6c5e><div class="left_cont" data-v-a6ac6c5e><div class="banner" data-v-a6ac6c5e>  <img src="https://static-de.echemi.com/_nuxt/img/pharma.2abe73b.jpg" alt="Pharma News" data-v-a6ac6c5e>  </div> <h1 class="special_font cate_name" data-v-a6ac6c5e></h1> <div class="list_box" data-v-a6ac6c5e><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2010423.html" data-v-a6ac6c5e><img alt="The Race for China's Next Top Diabetes Drug: Winsunny Pharmaceutical and Yiheng Pharma Vie for Pioglitazone and Metformin Combination" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2010423.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>The Race for China's Next Top Diabetes Drug: Winsunny Pharmaceutical and Yiheng Pharma Vie for Pioglitazone and Metformin Combination</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-12</div> <div class="description" data-v-a6ac6c5e>The news quickly garnered widespread attention as it heralded the arrival of a new player in a high-profile drug market competition.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2010379.html" data-v-a6ac6c5e><img alt="Harbour Biomed Regains Global Rights to HBM7008" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2010379.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Harbour Biomed Regains Global Rights to HBM7008</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-09</div> <div class="description" data-v-a6ac6c5e>On August 9, 2024, the company announced that it had successfully won back global development and commercialization rights to HBM7008 from Cullinan Oncology.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2010378.html" data-v-a6ac6c5e><img alt="Iovance's TIL Therapy Generates $12.8 Million in First Quarter Sales" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2010378.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Iovance's TIL Therapy Generates $12.8 Million in First Quarter Sales</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-09</div> <div class="description" data-v-a6ac6c5e>Iovance is building Amtagvi, an immune cell therapy product based on the company's unique autotumor-infiltrating lymphocyte (TIL) technology.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2010377.html" data-v-a6ac6c5e><img alt="The Menopause Health Market: Where New Opportunities and Challenges Meet" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2010377.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>The Menopause Health Market: Where New Opportunities and Challenges Meet</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-09</div> <div class="description" data-v-a6ac6c5e>When discussing the broad landscape of women's health, female menopause is undoubtedly a focus of attention.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2010353.html" data-v-a6ac6c5e><img alt="Novartis' Rare Disease Drug Fabhalta Wins FDA Approval for IgAN" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2010353.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Novartis' Rare Disease Drug Fabhalta Wins FDA Approval for IgAN</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-08</div> <div class="description" data-v-a6ac6c5e>A revolutionary drug developed by Novartis Pharmaceuticals, designated for the treatment of immunoglobulin A kidney disease (IgAN). A rare but widespread kidney disease.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2010352.html" data-v-a6ac6c5e><img alt="After 2023 Snub, Amneal Clinches Approval for Extended-Release Parkinson's Disease Med Crexont" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2010352.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>After 2023 Snub, Amneal Clinches Approval for Extended-Release Parkinson's Disease Med Crexont</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-08</div> <div class="description" data-v-a6ac6c5e>Amax Pharmaceuticals finally ushered in a brilliant victory in the United States, its signature innovative delayed release Parkinson's disease treatment drug - Crexont, successfully obtained the authoritative approval of the United States FDA.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2010351.html" data-v-a6ac6c5e><img alt="Humanwell Healthcare Reports 3.86% Revenue Growth in H1 2024" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2010351.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Humanwell Healthcare Reports 3.86% Revenue Growth in H1 2024</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-08</div> <div class="description" data-v-a6ac6c5e>The latest release shows that Humanwell Healthcare has delivered remarkable results in the first half of 2024, demonstrating excellent market performance.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2010350.html" data-v-a6ac6c5e><img alt="The Fast and Furious of the Pharmaceutical Industry: Tragedy and Reflection on Accelerated Approval of Drugs" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2010350.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>The Fast and Furious of the Pharmaceutical Industry: Tragedy and Reflection on Accelerated Approval of Drugs</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-08</div> <div class="description" data-v-a6ac6c5e>An amyotrophic lateral sclerosis (ALS) drug with annual sales of $400 million has been mockingly likened by industry analysts to &quot;its efficacy is not as cool as mints&quot;.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2010349.html" data-v-a6ac6c5e><img alt="Regulatory Challenges of Gene Therapy and Cancer Drugs: Industry Trends Behind the Withdrawal of Zydelig and FDA's Response" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2010349.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Regulatory Challenges of Gene Therapy and Cancer Drugs: Industry Trends Behind the Withdrawal of Zydelig and FDA's Response</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-08</div> <div class="description" data-v-a6ac6c5e>In 2022, Gilead announced that it would voluntarily withdraw Zydelig from the U.S. market for two lymphoma treatments, a full six years after it suspended the trial due to patient deaths.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002740.html" data-v-a6ac6c5e><img alt="Boehringer Ingelheim's Path to Cancer Research and development: From Acquisitions to the Rise of Innovative Drugs" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002740.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Boehringer Ingelheim's Path to Cancer Research and development: From Acquisitions to the Rise of Innovative Drugs</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-07</div> <div class="description" data-v-a6ac6c5e>On July 29, Boehringer Ingelheim announced a major acquisition, with plans to buy Nerio Therapeutics for $1.3 billion.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002697.html" data-v-a6ac6c5e><img alt="Biopharma Star Genor Bio Inks Mega Deal to Take its Dual-Targeting Antibody Overseas" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002697.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Biopharma Star Genor Bio Inks Mega Deal to Take its Dual-Targeting Antibody Overseas</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-06</div> <div class="description" data-v-a6ac6c5e>Recently, the Hong Kong stock market's innovative pharmaceutical giant - Genor Biological (06998.HK) and the United States biotechnology company TRC2004,Inc.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002696.html" data-v-a6ac6c5e><img alt="Huarun Acquires 62 Billion Yuan Stake in Chinese Medicine Giant" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002696.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Huarun Acquires 62 Billion Yuan Stake in Chinese Medicine Giant</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-06</div> <div class="description" data-v-a6ac6c5e>China's pharmaceutical industry ushered in a major equity change, China Resources Sanjiuannounced that it will buy 28% of Tasly's shares at a high price of 6.212 billion yuan, which marks another major expansion of China Resources Pharmaceutical territory</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002648.html" data-v-a6ac6c5e><img alt="The Blessing for 147 Million 'Hair Loss People': JAK Inhibitors Breakthrough in Alopecia Areata Treatment" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002648.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>The Blessing for 147 Million 'Hair Loss People': JAK Inhibitors Breakthrough in Alopecia Areata Treatment</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-05</div> <div class="description" data-v-a6ac6c5e>In the bright river of stars in the field of medicine, a new star is rising slowly, which has lit up the light of hope for countless patients with alopecia areata.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002558.html" data-v-a6ac6c5e><img alt="Unexpected Setback in Rare Disease Drug Development: Takeaways from Takeda's Phase 3 Trial Failure" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002558.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Unexpected Setback in Rare Disease Drug Development: Takeaways from Takeda's Phase 3 Trial Failure</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-02</div> <div class="description" data-v-a6ac6c5e>The results will undoubtedly bring takeda pharmaceuticals of new drug research and development of the road for a certain amount of uncertainty.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002557.html" data-v-a6ac6c5e><img alt="The Vanishing RSV Vaccine: A Billion-Dollar Market Shrinks" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002557.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>The Vanishing RSV Vaccine: A Billion-Dollar Market Shrinks</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-02</div> <div class="description" data-v-a6ac6c5e>RSV vaccine was known as a shining star in the pharmaceutical industry, and its market potential was placed high hopes by investors and experts, like an infinite blue ocean.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002556.html" data-v-a6ac6c5e><img alt="$8.7 Billion Deal! AbbVie Completes Major Acquisition" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002556.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>$8.7 Billion Deal! AbbVie Completes Major Acquisition</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-02</div> <div class="description" data-v-a6ac6c5e>Abbvie company on August 1, 2024 announced a major industry trends, has won regulatory approval across the globe, success with $8.7 billion purchased biotechnology company focused on neuroscience Cerevel Therapeutics.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002554.html" data-v-a6ac6c5e><img alt="Non - Addictive Pain Relief: Vertex 's will be Analgesic Drug VX - 548 Enters the Race" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002554.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Non - Addictive Pain Relief: Vertex 's will be Analgesic Drug VX - 548 Enters the Race</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-02</div> <div class="description" data-v-a6ac6c5e>Vertex Pharmaceuticals, known for its outstanding contributions to the treatment of rare diseases, has recently made significant breakthroughs in new medical fields.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002553.html" data-v-a6ac6c5e><img alt="Semaglutide's Unstoppable Rise as the "Drug King"" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002553.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Semaglutide's Unstoppable Rise as the "Drug King"</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-02</div> <div class="description" data-v-a6ac6c5e>The development of semaglutide, a miracle drug, is a saga of challenges and breakthroughs.</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002514.html" data-v-a6ac6c5e><img alt="Pfizer Terminates DMD Gene Therapy Development, Cuts 210 Jobs" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002514.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>Pfizer Terminates DMD Gene Therapy Development, Cuts 210 Jobs</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-01</div> <div class="description" data-v-a6ac6c5e>Recently, Pfizer, the world-famous pharmaceutical giant, announced a remarkable decision to officially terminate the development process of its gene therapy Fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy (DMD).</div></div></div><div class="list_item flex" data-v-a6ac6c5e><div class="img_box" data-v-a6ac6c5e><a href="/cms/2002513.html" data-v-a6ac6c5e><img alt="From a Diversified Conglomerate to a CDMO Rising Star: Lotte's Foray into Biopharmaceuticals Aims to Conquer the Global Market" data-v-a6ac6c5e></a></div> <div class="info_box" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><a href="/cms/2002513.html" data-v-a6ac6c5e><h3 data-v-a6ac6c5e>From a Diversified Conglomerate to a CDMO Rising Star: Lotte's Foray into Biopharmaceuticals Aims to Conquer the Global Market</h3></a></div> <div class="date" data-v-a6ac6c5e>2024-08-01</div> <div class="description" data-v-a6ac6c5e>In July 2024, Lotte biological agents in Incheon, South Korea pine island biological park to start the construction of the new plant, marks its layout in the field of biological medicine took a substantive step.</div></div></div> <div query="[object Object]" class="page-wrap" data-v-ab1b21b2 data-v-a6ac6c5e> <span class="li-page disabled" data-v-ab1b21b2><i class="iconfont icon-youhua" data-v-ab1b21b2></i></span> <ul data-v-ab1b21b2><li class="active" data-v-ab1b21b2><a href="/cms-news/pharmaceutical.html?page=1" data-v-ab1b21b2><span data-v-ab1b21b2>1</span></a></li><li data-v-ab1b21b2><a href="/cms-news/pharmaceutical.html?page=2" data-v-ab1b21b2><span data-v-ab1b21b2>2</span></a></li><li data-v-ab1b21b2><a href="/cms-news/pharmaceutical.html?page=3" data-v-ab1b21b2><span data-v-ab1b21b2>3</span></a></li><li data-v-ab1b21b2><a href="/cms-news/pharmaceutical.html?page=4" data-v-ab1b21b2><span data-v-ab1b21b2>4</span></a></li><li data-v-ab1b21b2><a href="/cms-news/pharmaceutical.html?page=5" data-v-ab1b21b2><span data-v-ab1b21b2>5</span></a></li><li data-v-ab1b21b2><a href="/cms-news/pharmaceutical.html?page=6" data-v-ab1b21b2><span data-v-ab1b21b2>6</span></a></li><li data-v-ab1b21b2><a href="/cms-news/pharmaceutical.html?page=7" data-v-ab1b21b2><span data-v-ab1b21b2>7</span></a></li><li data-v-ab1b21b2><a href="/cms-news/pharmaceutical.html?page=8" data-v-ab1b21b2><span data-v-ab1b21b2>8</span></a></li><li data-v-ab1b21b2><span data-v-ab1b21b2>···</span></li> <li class="notallowed" data-v-ab1b21b2><span data-v-ab1b21b2>97</span></li></ul> <span class="li-page" data-v-ab1b21b2><a rel="next" href="/cms-news/pharmaceutical.html?page=2" data-v-ab1b21b2><i class="iconfont icon-zuohua" data-v-ab1b21b2></i></a></span> </div></div></div> <div class="right_cont" data-v-a6ac6c5e><div class="for_left_border" data-v-a6ac6c5e><div class="right_common news" data-v-a6ac6c5e><div class="title" data-v-a6ac6c5e><h2 class="special_font" data-v-a6ac6c5e>Heiße Nachrichten</h2></div> <ul data-v-a6ac6c5e><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/597549.html" data-v-a6ac6c5e><p title="Top 10 Global CDMO Rankings im Jahr 2022" data-v-a6ac6c5e>Top 10 Global CDMO Rankings im Jahr 2022</p></a></div></li><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/124962.html" data-v-a6ac6c5e><p title="Sanofi und Translate Bio mRNA COVID-19 Impfstoffkandidat induziert hohe Antikörper" data-v-a6ac6c5e>Sanofi und Translate Bio mRNA COVID-19 Impfstoffkandidat induziert hohe Antikörper</p></a></div></li><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/132623.html" data-v-a6ac6c5e><p title="Prognose der TOP 10 der weltweit meistverkauften Medikamente im Jahr 2021" data-v-a6ac6c5e>Prognose der TOP 10 der weltweit meistverkauften Medikamente im Jahr 2021</p></a></div></li><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/110494.html" data-v-a6ac6c5e><p title="Lillys GLP-1 und Tirzepatide starten klinische Phase-III-Studie" data-v-a6ac6c5e>Lillys GLP-1 und Tirzepatide starten klinische Phase-III-Studie</p></a></div></li><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/120365.html" data-v-a6ac6c5e><p title="Klinische Studien zum COVID-19-Impfstoff AZD1222 in Großbritannien wieder aufgenommen" data-v-a6ac6c5e>Klinische Studien zum COVID-19-Impfstoff AZD1222 in Großbritannien wieder aufgenommen</p></a></div></li><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/210247.html" data-v-a6ac6c5e><p title="China State Drug Administration offiziell zugelassen Semaglutid für Typ-2-Diabetes" data-v-a6ac6c5e>China State Drug Administration offiziell zugelassen Semaglutid für Typ-2-Diabetes</p></a></div></li><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/145925.html" data-v-a6ac6c5e><p title="Top 30 der meistverkauften Onkologie-Medikamente der Welt im Jahr 2020" data-v-a6ac6c5e>Top 30 der meistverkauften Onkologie-Medikamente der Welt im Jahr 2020</p></a></div></li><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/852553.html" data-v-a6ac6c5e><p title="Neueste Nachrichten! Chinas erster KRAS G12D-Inhibitor für den klinischen Einsatz zugelassen" data-v-a6ac6c5e>Neueste Nachrichten! Chinas erster KRAS G12D-Inhibitor für den klinischen Einsatz zugelassen</p></a></div></li><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/120366.html" data-v-a6ac6c5e><p title="Pfizer und BioNTech schlagen Erweiterung der zulassungsrelevanten COVID-19-Impfstoffstudie vor" data-v-a6ac6c5e>Pfizer und BioNTech schlagen Erweiterung der zulassungsrelevanten COVID-19-Impfstoffstudie vor</p></a></div></li><li data-v-a6ac6c5e><div data-v-a6ac6c5e><i data-v-a6ac6c5e></i> <a href="https://de.echemi.com/cms/325484.html" data-v-a6ac6c5e><p title="Das Blockbuster-Produkt von AbbVie für atopische Dermatitis, Upadacitinib, wurde für die Vermarktung in der EU und Japan zugelassen" data-v-a6ac6c5e>Das Blockbuster-Produkt von AbbVie für atopische Dermatitis, Upadacitinib, wurde für die Vermarktung in der EU und Japan zugelassen</p></a></div></li></ul></div></div></div></div></div></div></div> <div data-v-6eba653e><div class="footer" data-v-6eba653e><div class="max_width" data-v-6eba653e><div class="width_1050" data-v-6eba653e><p class="tip" data-v-6eba653e>Trade Alert - Bieten Sie die neuesten Produkttrends und Branchennachrichten direkt in Ihre Inbox an. <br> (Wir geben nie einem Drittanbiter Ihre E-Mail-Adresse)</p> <div class="input_box clearfix" data-v-6eba653e><input type="text" placeholder="Geben Sie Ihre E-Mail-Adresse ein" value="" data-v-6eba653e> <div class="subscribe_btn" data-v-6eba653e>Abonnieren</div></div> <div class="footer_box1 clearfix" data-v-6eba653e><div class="footer_list" data-v-6eba653e><div class="title" data-v-6eba653e>Über Uns</div> <div class="li" data-v-6eba653e><a href="/echemi.html" data-v-6eba653e>Über Echemi.com</a> <a href="/contactinfo.html" data-v-6eba653e>Kontaktieren Sie Uns</a></div></div> <div class="footer_list" data-v-6eba653e><div class="title" data-v-6eba653e>Kaufen Sie auf Echemi.com</div> <div class="li" data-v-6eba653e><a href="/searchInquiry.html" data-v-6eba653e>Angebotsanfrage</a></div></div> <div class="footer_list" data-v-6eba653e><div class="title" data-v-6eba653e>Verkaufen Sie auf Echemi.com</div> <div class="li" data-v-6eba653e><a href="/vipApply.html" data-v-6eba653e>Lieferantenmitgliedschaft</a></div></div> <div class="footer_list" data-v-6eba653e><div class="title" data-v-6eba653e>Hilfecenter</div> <div class="li" data-v-6eba653e><a href="/conditions.html" data-v-6eba653e>Nutzungsbestimmungen</a> <a href="/privacy.html" data-v-6eba653e>Datenschutzerklärung</a></div></div></div> <div class="icon_box" data-v-6eba653e><span data-v-6eba653e>Folgen Sie Uns</span> <a rel="external nofollow" href="https://www.facebook.com/echemii/" target="_blank" data-v-6eba653e><i class="iconfont" data-v-6eba653e></i></a> <a rel="external nofollow" href="https://twitter.com/Echemiqd" target="_blank" data-v-6eba653e><i class="iconfont" data-v-6eba653e></i></a> <a rel="external nofollow" href="http://www.linkedin.com/company/qingdao-echemi-technology-co-ltd" target="_blank" data-v-6eba653e><i class="iconfont" data-v-6eba653e></i></a></div> <div class="footer_box2" data-v-6eba653e> Liste der Top 100 Unternehmen für industrielle Digitalisierung in China <br data-v-6eba653e> Das Referat für die Ausarbeitung der „Spezifikation und Verwaltung der selbsterstellten grenzüberschreitenden E-Commerce-Website" des CCPIT</div> <p class="reference" data-v-6eba653e>鲁ICP备16009155号-1 | Copyright@Qingdao ECHEMI Digitizing Technology Co., Ltd.</p></div></div></div> <aside class="aside_box" data-v-6eba653e><div class="aside_btn go_top" data-v-6eba653e><i class="iconfont icon-huidaodingbu" data-v-6eba653e></i></div> <a href="javascript:void(0)" rel="nofollow" data-v-6eba653e><div class="aside_btn aside_suggestion" data-v-6eba653e><i class="iconfont" data-v-6eba653e></i> <div class="tips" data-v-6eba653e>Beschwerde</div></div></a> <a href="tel:86-532-55717492" rel="nofollow" data-v-6eba653e><div class="aside_btn" data-v-6eba653e><i class="iconfont" data-v-6eba653e></i> <div class="tips" data-v-6eba653e>86-532-55729510</div></div></a> <a href="javascript:void(0);" rel="nofollow" data-v-6eba653e><div class="aside_btn skype" data-v-6eba653e><i class="iconfont icon-skype" data-v-6eba653e></i> <div class="tips" data-v-6eba653e>Skype</div></div></a> <a href="https://api.whatsapp.com/send?phone=8615853232676" target="_blank" rel="nofollow" data-v-6eba653e><div class="aside_btn" data-v-6eba653e><i class="iconfont" data-v-6eba653e></i> <div class="tips" data-v-6eba653e>WhatsApp</div></div></a> </aside> <div data-v-44f33a33 data-v-6eba653e><div class="el-dialog__wrapper messageForm" style="display:none;" data-v-44f33a33><div role="dialog" aria-modal="true" aria-label="Beschwerde" class="el-dialog" style="margin-top:15vh;width:550px;"><div class="el-dialog__header"><span class="el-dialog__title">Beschwerde</span><button type="button" aria-label="Close" class="el-dialog__headerbtn"><i class="el-dialog__close el-icon el-icon-close"></i></button></div></div></div></div> <div data-v-37c3f8b7 data-v-6eba653e><div class="el-dialog__wrapper noCloseDialog" style="display:none;" data-v-37c3f8b7><div role="dialog" aria-modal="true" aria-label="Tipps" class="el-dialog" style="margin-top:15vh;width:550px;"><div class="el-dialog__header"><span class="el-dialog__title">Tipps</span><button type="button" aria-label="Close" class="el-dialog__headerbtn"><i class="el-dialog__close el-icon el-icon-close"></i></button></div><div class="el-dialog__footer"><div class="dialog-footer flex flex_b" data-v-37c3f8b7><div class="button_red_blank button" data-v-37c3f8b7>Skype Herunterladen</div> <div class="button_red_bg button" data-v-37c3f8b7>Skype öffnen</div></div></div></div></div></div></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v){return {layout:"default",data:[{secondName:m,forParams:{catName:m,catId:d},forQuery:{page:1},tkdInfo:{id:"4ce48758-76d0-11ed-890b-fa163eba3858",tkdPageId:"PDE024",tkdTitle:"Big Pharma News Today, Neuigkeiten aus der Pharmabranche - ECHEMI",tkdKeywords:"Tägliche Pharma-Nachrichten, Pharma-Wirtschaftsnachrichten, internationale Pharma-Nachrichten, aktuelle Nachrichten aus der pharmazeutischen Industrie",tkdDescription:"Holen Sie sich die neuesten und aktuellen Nachrichten aus der globalen Pharmaindustrie mit Neuigkeiten und Marketinganalysen von Top-Pharmaunternehmen. Behalten Sie die weltweiten Pharmatrends von ECHEMI im Auge.",cmsKeywords:a,sharePicture:a,sharePictureAddress:a},cmsNewsList:[{contentid:"2010423",catid:d,catname:e,catabbr:f,modelid:c,title:"The Race for China's Next Top Diabetes Drug: Winsunny Pharmaceutical and Yiheng Pharma Vie for Pioglitazone and Metformin Combination",urlName:"the-race-for-china-s-next-top-diabetes-drug-winsunny-pharmaceutical-and-yiheng-pharma-vie-for-pioglitazone-and-metformin-combination",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0812\u002F1723454731264.png",published:"2024-08-12",publishedDatetime:"2024-08-12 17:25:32",source:g,description:"The news quickly garnered widespread attention as it heralded the arrival of a new player in a high-profile drug market competition.",pv:"33",editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2010379",catid:d,catname:e,catabbr:f,modelid:c,title:"Harbour Biomed Regains Global Rights to HBM7008",urlName:"harbour-biomed-regains-global-rights-to-hbm7008",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0809\u002F1723193260149.png",published:k,publishedDatetime:n,source:g,description:"On August 9, 2024, the company announced that it had successfully won back global development and commercialization rights to HBM7008 from Cullinan Oncology.",pv:"141",editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2010378",catid:d,catname:e,catabbr:f,modelid:c,title:"Iovance's TIL Therapy Generates $12.8 Million in First Quarter Sales",urlName:"iovance-s-til-therapy-generates-128-million-in-first-quarter-sales",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0809\u002F1723193231380.png",published:k,publishedDatetime:n,source:g,description:"Iovance is building Amtagvi, an immune cell therapy product based on the company's unique autotumor-infiltrating lymphocyte (TIL) technology.",pv:"137",editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2010377",catid:d,catname:e,catabbr:f,modelid:c,title:"The Menopause Health Market: Where New Opportunities and Challenges Meet",urlName:"the-menopause-health-market-where-new-opportunities-and-challenges-meet",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0809\u002F1723193186630.png",published:k,publishedDatetime:"2024-08-09 16:46:00",source:g,description:"When discussing the broad landscape of women's health, female menopause is undoubtedly a focus of attention.",pv:"122",editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2010353",catid:d,catname:e,catabbr:f,modelid:c,title:"Novartis' Rare Disease Drug Fabhalta Wins FDA Approval for IgAN",urlName:"novartis-rare-disease-drug-fabhalta-wins-fda-approval-for-igan",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0808\u002F1723105633202.png",published:i,publishedDatetime:"2024-08-08 16:27:00",source:g,description:"A revolutionary drug developed by Novartis Pharmaceuticals, designated for the treatment of immunoglobulin A kidney disease (IgAN). A rare but widespread kidney disease.",pv:o,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2010352",catid:d,catname:e,catabbr:f,modelid:c,title:"After 2023 Snub, Amneal Clinches Approval for Extended-Release Parkinson's Disease Med Crexont",urlName:"after-2023-snub-amneal-clinches-approval-for-extended-release-parkinson-s-disease-med-crexont",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0808\u002F1723105586446.png",published:i,publishedDatetime:"2024-08-08 16:26:00",source:g,description:"Amax Pharmaceuticals finally ushered in a brilliant victory in the United States, its signature innovative delayed release Parkinson's disease treatment drug - Crexont, successfully obtained the authoritative approval of the United States FDA.",pv:"12",editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2010351",catid:d,catname:e,catabbr:f,modelid:c,title:"Humanwell Healthcare Reports 3.86% Revenue Growth in H1 2024",urlName:"humanwell-healthcare-reports-386-revenue-growth-in-h1-2024",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0808\u002F1723105527443.png",published:i,publishedDatetime:"2024-08-08 16:25:29",source:g,description:"The latest release shows that Humanwell Healthcare has delivered remarkable results in the first half of 2024, demonstrating excellent market performance.",pv:p,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2010350",catid:d,catname:e,catabbr:f,modelid:c,title:"The Fast and Furious of the Pharmaceutical Industry: Tragedy and Reflection on Accelerated Approval of Drugs",urlName:"the-fast-and-furious-of-the-pharmaceutical-industry-tragedy-and-reflection-on-accelerated-approval-of-drugs",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0808\u002F1723105495847.png",published:i,publishedDatetime:"2024-08-08 16:25:00",source:g,description:"An amyotrophic lateral sclerosis (ALS) drug with annual sales of $400 million has been mockingly likened by industry analysts to "its efficacy is not as cool as mints".",pv:"13",editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2010349",catid:d,catname:e,catabbr:f,modelid:c,title:"Regulatory Challenges of Gene Therapy and Cancer Drugs: Industry Trends Behind the Withdrawal of Zydelig and FDA's Response",urlName:"regulatory-challenges-of-gene-therapy-and-cancer-drugs-industry-trends-behind-the-withdrawal-of-zydelig-and-fda-s-response",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0808\u002F1723105441128.png",published:i,publishedDatetime:"2024-08-08 16:24:04",source:g,description:"In 2022, Gilead announced that it would voluntarily withdraw Zydelig from the U.S. market for two lymphoma treatments, a full six years after it suspended the trial due to patient deaths.",pv:q,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002740",catid:d,catname:e,catabbr:f,modelid:c,title:"Boehringer Ingelheim's Path to Cancer Research and development: From Acquisitions to the Rise of Innovative Drugs",urlName:"boehringer-ingelheim-s-path-to-cancer-research-and-development-from-acquisitions-to-the-rise-of-innovative-drugs",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0807\u002F1723024925381.png",published:"2024-08-07",publishedDatetime:"2024-08-07 18:02:08",source:g,description:"On July 29, Boehringer Ingelheim announced a major acquisition, with plans to buy Nerio Therapeutics for $1.3 billion.",pv:"53",editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002697",catid:d,catname:e,catabbr:f,modelid:c,title:"Biopharma Star Genor Bio Inks Mega Deal to Take its Dual-Targeting Antibody Overseas",urlName:"biopharma-star-genor-bio-inks-mega-deal-to-take-its-dual-targeting-antibody-overseas",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0806\u002F1722939244926.png",published:r,publishedDatetime:"2024-08-06 18:14:00",source:g,description:"Recently, the Hong Kong stock market's innovative pharmaceutical giant - Genor Biological (06998.HK) and the United States biotechnology company TRC2004,Inc.",pv:o,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002696",catid:d,catname:e,catabbr:f,modelid:c,title:"Huarun Acquires 62 Billion Yuan Stake in Chinese Medicine Giant",urlName:"huarun-acquires-62-billion-yuan-stake-in-chinese-medicine-giant",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0806\u002F1722939214984.png",published:r,publishedDatetime:"2024-08-06 18:13:37",source:g,description:"China's pharmaceutical industry ushered in a major equity change, China Resources Sanjiuannounced that it will buy 28% of Tasly's shares at a high price of 6.212 billion yuan, which marks another major expansion of China Resources Pharmaceutical territory",pv:l,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002648",catid:d,catname:e,catabbr:f,modelid:c,title:"The Blessing for 147 Million 'Hair Loss People': JAK Inhibitors Breakthrough in Alopecia Areata Treatment",urlName:"the-blessing-for-147-million-hair-loss-people-jak-inhibitors-breakthrough-in-alopecia-areata-treatment",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0805\u002F1722849423718.png",published:"2024-08-05",publishedDatetime:"2024-08-05 17:17:00",source:g,description:"In the bright river of stars in the field of medicine, a new star is rising slowly, which has lit up the light of hope for countless patients with alopecia areata.",pv:l,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002558",catid:d,catname:e,catabbr:f,modelid:c,title:"Unexpected Setback in Rare Disease Drug Development: Takeaways from Takeda's Phase 3 Trial Failure",urlName:"unexpected-setback-in-rare-disease-drug-development-takeaways-from-takeda-s-phase-3-trial-failure",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0802\u002F1722591087938.png",published:j,publishedDatetime:"2024-08-02 17:31:00",source:g,description:"The results will undoubtedly bring takeda pharmaceuticals of new drug research and development of the road for a certain amount of uncertainty.",pv:"152",editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002557",catid:d,catname:e,catabbr:f,modelid:c,title:"The Vanishing RSV Vaccine: A Billion-Dollar Market Shrinks",urlName:"the-vanishing-rsv-vaccine-a-billion-dollar-market-shrinks",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0802\u002F1722591043637.png",published:j,publishedDatetime:"2024-08-02 17:30:45",source:g,description:"RSV vaccine was known as a shining star in the pharmaceutical industry, and its market potential was placed high hopes by investors and experts, like an infinite blue ocean.",pv:p,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002556",catid:d,catname:e,catabbr:f,modelid:c,title:"$8.7 Billion Deal! AbbVie Completes Major Acquisition",urlName:"87-billion-deal-abbvie-completes-major-acquisition",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0802\u002F1722590989800.png",published:j,publishedDatetime:"2024-08-02 17:29:00",source:g,description:"Abbvie company on August 1, 2024 announced a major industry trends, has won regulatory approval across the globe, success with $8.7 billion purchased biotechnology company focused on neuroscience Cerevel Therapeutics.",pv:s,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002554",catid:d,catname:e,catabbr:f,modelid:c,title:"Non - Addictive Pain Relief: Vertex 's will be Analgesic Drug VX - 548 Enters the Race",urlName:"non-addictive-pain-relief-vertex-s-will-be-analgesic-drug-vx-548-enters-the-race",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0802\u002F1722590828988.png",published:j,publishedDatetime:"2024-08-02 17:27:12",source:g,description:"Vertex Pharmaceuticals, known for its outstanding contributions to the treatment of rare diseases, has recently made significant breakthroughs in new medical fields.",pv:s,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002553",catid:d,catname:e,catabbr:f,modelid:c,title:"Semaglutide's Unstoppable Rise as the \"Drug King\"",urlName:"semaglutide-s-unstoppable-rise-as-the-drug-king",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0802\u002F1722590791154.png",published:j,publishedDatetime:"2024-08-02 17:26:35",source:g,description:"The development of semaglutide, a miracle drug, is a saga of challenges and breakthroughs.",pv:q,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002514",catid:d,catname:e,catabbr:f,modelid:c,title:"Pfizer Terminates DMD Gene Therapy Development, Cuts 210 Jobs",urlName:"pfizer-terminates-dmd-gene-therapy-development-cuts-210-jobs",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0801\u002F1722505645316.png",published:t,publishedDatetime:"2024-08-01 17:47:27",source:g,description:"Recently, Pfizer, the world-famous pharmaceutical giant, announced a remarkable decision to officially terminate the development process of its gene therapy Fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy (DMD).",pv:"40",editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a},{contentid:"2002513",catid:d,catname:e,catabbr:f,modelid:c,title:"From a Diversified Conglomerate to a CDMO Rising Star: Lotte's Foray into Biopharmaceuticals Aims to Conquer the Global Market",urlName:"from-a-diversified-conglomerate-to-a-cdmo-rising-star-lotte-s-foray-into-biopharmaceuticals-aims-to-conquer-the-global-market",subtitle:b,infoUrl:b,tags:b,tagArray:a,originalTags:b,metaData:a,thumb:"https:\u002F\u002Fupload.echemi.com\u002F2024\u002F0801\u002F1722505606824.png",published:t,publishedDatetime:"2024-08-01 17:46:51",source:g,description:"In July 2024, Lotte biological agents in Incheon, South Korea pine island biological park to start the construction of the new plant, marks its layout in the field of biological medicine took a substantive step.",pv:l,editor:h,exhibitionStartDate:a,exhibitionEndDate:a,exhibitionDateShow:a,city:a,country:a,cas:a,industry:a}],totalCount:1931,cmsHotList:[{contentid:"597549",thumb:"https:\u002F\u002Fupload.echemi.com\u002F2017\u002F0526\u002F1495768910485.png",title:"Top 10 Global CDMO Rankings im Jahr 2022",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F597549.html",modelid:c},{contentid:"124962",thumb:u,title:"Sanofi und Translate Bio mRNA COVID-19 Impfstoffkandidat induziert hohe Antikörper",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F124962.html",modelid:c},{contentid:"132623",thumb:"https:\u002F\u002Fupload.echemi.com\u002F2018\u002F0621\u002F1529561063568.jpg",title:"Prognose der TOP 10 der weltweit meistverkauften Medikamente im Jahr 2021",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F132623.html",modelid:c},{contentid:"110494",thumb:"https:\u002F\u002Fupload.echemi.com\u002F2020\u002F0630\u002F1593502009310.jpg",title:"Lillys GLP-1 und Tirzepatide starten klinische Phase-III-Studie",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F110494.html",modelid:c},{contentid:"120365",thumb:u,title:"Klinische Studien zum COVID-19-Impfstoff AZD1222 in Großbritannien wieder aufgenommen",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F120365.html",modelid:c},{contentid:"210247",thumb:"https:\u002F\u002Fupload.echemi.com\u002F2021\u002F0429\u002F1619676636664.jpg",title:"China State Drug Administration offiziell zugelassen Semaglutid für Typ-2-Diabetes",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F210247.html",modelid:c},{contentid:"145925",thumb:"https:\u002F\u002Fupload.echemi.com\u002F2018\u002F0321\u002F1521616362475.png",title:"Top 30 der meistverkauften Onkologie-Medikamente der Welt im Jahr 2020",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F145925.html",modelid:c},{contentid:"852553",thumb:"https:\u002F\u002Fupload.echemi.com\u002F2019\u002F1104\u002F1572830161328.jpg",title:"Neueste Nachrichten! Chinas erster KRAS G12D-Inhibitor für den klinischen Einsatz zugelassen",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F852553.html",modelid:c},{contentid:"120366",thumb:"https:\u002F\u002Fupload.echemi.com\u002F2020\u002F0420\u002F1587374884773.jpg",title:"Pfizer und BioNTech schlagen Erweiterung der zulassungsrelevanten COVID-19-Impfstoffstudie vor",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F120366.html",modelid:c},{contentid:"325484",thumb:"https:\u002F\u002Fupload.echemi.com\u002F2019\u002F0520\u002F1558324236709.jpg",title:"Das Blockbuster-Produkt von AbbVie für atopische Dermatitis, Upadacitinib, wurde für die Vermarktung in der EU und Japan zugelassen",infoUrl:"https:\u002F\u002Fde.echemi.com\u002Fcms\u002F325484.html",modelid:c}]}],fetch:{},error:a,state:{locale:"de",pagination:{offset:0}},serverRendered:true,routePath:"\u002Fcms-news\u002Fpharmaceutical.html",config:{_app:{basePath:v,assetsPath:v,cdnURL:"https:\u002F\u002Fstatic-de.echemi.com\u002F_nuxt\u002F"}}}}(null,"","1","107","Pharmaceutical","P","ECHEMI","Kim","2024-08-08","2024-08-02","2024-08-09","24","Pharma News","2024-08-09 16:47:00","149","20","17","2024-08-06","18","2024-08-01","https:\u002F\u002Fupload.echemi.com\u002F2020\u002F0617\u002F1592377285382.jpg","\u002F"));</script><script src="https://static-de.echemi.com/_nuxt/79ec1eb.js" defer></script><script src="https://static-de.echemi.com/_nuxt/db56bde.js" defer></script><script src="https://static-de.echemi.com/_nuxt/9919ef3.js" defer></script><script src="https://static-de.echemi.com/_nuxt/6159f0f.js" defer></script><script src="https://static-de.echemi.com/_nuxt/8972da6.js" defer></script><script src="https://static-de.echemi.com/_nuxt/d173603.js" defer></script><script src="https://static-de.echemi.com/_nuxt/d2fee69.js" defer></script><script src="https://static-de.echemi.com/_nuxt/4fb1842.js" defer></script> </body> </html>